[go: up one dir, main page]

EP2393359A4 - Verbundene dibenzimidazolderivate - Google Patents

Verbundene dibenzimidazolderivate

Info

Publication number
EP2393359A4
EP2393359A4 EP20100739272 EP10739272A EP2393359A4 EP 2393359 A4 EP2393359 A4 EP 2393359A4 EP 20100739272 EP20100739272 EP 20100739272 EP 10739272 A EP10739272 A EP 10739272A EP 2393359 A4 EP2393359 A4 EP 2393359A4
Authority
EP
European Patent Office
Prior art keywords
dibenzimidazole derivatives
linked dibenzimidazole
linked
derivatives
dibenzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20100739272
Other languages
English (en)
French (fr)
Other versions
EP2393359A1 (de
Inventor
Yao-Ling Qiu
Ce Wang
Lu Ying
Xiaowen Peng
Yat Sun Or
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enanta Pharmaceuticals Inc
Original Assignee
Enanta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharmaceuticals Inc filed Critical Enanta Pharmaceuticals Inc
Publication of EP2393359A1 publication Critical patent/EP2393359A1/de
Publication of EP2393359A4 publication Critical patent/EP2393359A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20100739272 2009-02-09 2010-02-09 Verbundene dibenzimidazolderivate Withdrawn EP2393359A4 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15107909P 2009-02-09 2009-02-09
US15322409P 2009-02-17 2009-02-17
US15323109P 2009-02-17 2009-02-17
US15611009P 2009-02-27 2009-02-27
US15623909P 2009-02-27 2009-02-27
PCT/US2010/023645 WO2010091413A1 (en) 2009-02-09 2010-02-09 Linked dibenzimidazole derivatives

Publications (2)

Publication Number Publication Date
EP2393359A1 EP2393359A1 (de) 2011-12-14
EP2393359A4 true EP2393359A4 (de) 2012-10-03

Family

ID=42542427

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20100739272 Withdrawn EP2393359A4 (de) 2009-02-09 2010-02-09 Verbundene dibenzimidazolderivate

Country Status (2)

Country Link
EP (1) EP2393359A4 (de)
WO (1) WO2010091413A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9120779B2 (en) 2008-12-03 2015-09-01 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
DK2373172T3 (da) * 2008-12-03 2013-10-21 Presidio Pharmaceuticals Inc Hcv-ns5a-hæmmere
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
WO2010075380A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5734956B2 (ja) 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
SI2430014T1 (sl) 2009-05-13 2015-10-30 Gilead Pharmasset Llc Protivirusne spojine
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2435424B1 (de) * 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Aus drei miteinander verbundenen aryleinheiten zusammengesetzte antivirale verbindungen zur behandlung von krankheiten wie hepatitis c
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2435421A1 (de) * 2009-05-29 2012-04-04 Schering Corporation Aus drei in einer reihe ausgerichteten aryleinheiten zusammengesetzte antivirale verbindungen zur behandlung von krankheiten wie hepatitis c
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
RS53856B1 (en) 2009-06-11 2015-08-31 Abbvie Bahamas Ltd. HETEROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
EP2454254A2 (de) 2009-07-16 2012-05-23 Vertex Pharmaceuticals Incorporated Benzimidazol-analoga zur behandlung oder vorbeugung von flavivirus-nfektionen
CA2768638A1 (en) * 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
BR112012004969A2 (pt) 2009-09-03 2019-09-24 Tibotec Pharm Ltd derivados de bis-benzimidazol
WO2011028596A1 (en) 2009-09-04 2011-03-10 Glaxosmithkline Llc Chemical compounds
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010330862B2 (en) 2009-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2013521279A (ja) * 2010-03-04 2013-06-10 エナンタ ファーマシューティカルズ インコーポレイテッド Hcv複製の阻害剤としての医薬併用剤
CN102869657A (zh) 2010-03-24 2013-01-09 沃泰克斯药物股份有限公司 用于治疗或预防黄病毒感染的类似物
TW201139438A (en) * 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
WO2011150243A1 (en) * 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2585447A2 (de) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Verbindungen und verfahren zur behandlung oder vorbeugung von flavivirus-infektionen
EP2585448A1 (de) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Verbindungen und verfahren zur behandlung oder vorbeugung von flavivirus-infektionen
JP2013534249A (ja) 2010-08-17 2013-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス科ウイルス感染の処置または予防のための化合物および方法
AU2014203655B2 (en) * 2010-10-13 2016-07-07 Abbvie Ireland Unlimited Company Anti-viral compounds
EP2651923A4 (de) * 2010-12-15 2014-06-18 Abbvie Inc Antivirale verbindungen
EP2651927A4 (de) * 2010-12-15 2014-06-04 Abbvie Inc Antivirale verbindungen
EP2651925A4 (de) * 2010-12-15 2014-06-18 Abbvie Inc Antivirale verbindungen
EP2651885A1 (de) * 2010-12-16 2013-10-23 Abbvie Inc. Antivirale verbindungen
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) * 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
AU2012262338B2 (en) * 2011-05-27 2016-12-08 Achillion Pharmaceuticals, Inc. Substituted Aliphanes, Cyclophanes, Heteraphanes, Heterophanes, Hetero-Heteraphanes and Metallocenes Useful for Treating HCV Infections
AU2012286853A1 (en) 2011-07-26 2013-05-02 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
PE20141056A1 (es) 2011-09-16 2014-09-05 Gilead Pharmasset Llc Metodos para el tratamiento de vhc
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
MX340033B (es) 2011-12-28 2016-06-21 Janssen Sciences Ireland Uc Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2827876A4 (de) 2012-03-22 2015-10-28 Alios Biopharma Inc Pharmazeutische kombinationen mit einem thionucleotidanalog
TWI610916B (zh) * 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
MX351816B (es) 2013-01-31 2017-10-30 Gilead Pharmasset Llc Formulacion de combinacion de dos compuestos antivirales.
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN105272972B (zh) * 2014-05-30 2018-12-11 上海唐润医药科技有限公司 具有抗病毒活性的苯并杂环己二烯衍生物
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN108884033B (zh) * 2016-03-31 2021-03-09 杨森制药公司 作为登革病毒复制抑制剂的经取代的吲哚衍生物
CR20180496A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TWI758480B (zh) 2017-05-22 2022-03-21 美商健生醫藥公司 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物(二)
SI3630724T1 (sl) 2017-05-22 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
IL300572A (en) 2018-02-13 2023-04-01 Gilead Sciences Inc PD–1/PD–L1 inhibitors
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
JP7105359B2 (ja) 2018-07-13 2022-07-22 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
EP3870566A1 (de) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1-inhibitoren
EP4341266A1 (de) 2021-05-21 2024-03-27 Gilead Sciences, Inc. Pentacyclische derivate als zika-virus-hemmer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133326A1 (en) * 2005-06-06 2006-12-14 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2008021927A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2010017401A1 (en) * 2008-08-07 2010-02-11 Bristol-Myers Squibb Company Bi-1h-benzimidazoles as hepatitis c virus inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935982A (en) * 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
EP2335700A1 (de) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C Virus Polymerase Inhibitoren mit heterobicylischer Struktur
GB0229518D0 (en) * 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
DE602004018363D1 (de) * 2003-10-27 2009-01-22 Vertex Pharma Kombinationen für die hcv-behandlung
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133326A1 (en) * 2005-06-06 2006-12-14 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2008021927A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2010017401A1 (en) * 2008-08-07 2010-02-11 Bristol-Myers Squibb Company Bi-1h-benzimidazoles as hepatitis c virus inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010091413A1 *

Also Published As

Publication number Publication date
WO2010091413A1 (en) 2010-08-12
EP2393359A1 (de) 2011-12-14

Similar Documents

Publication Publication Date Title
EP2393359A4 (de) Verbundene dibenzimidazolderivate
HK1173142A1 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives n1--5-
ZA201203205B (en) Benzimidazole-imidazole derivatives
HK1172893A1 (en) 5-fluoropyrimidinone derivatives 5-
GB0912778D0 (en) Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) Fused aminodihydropyrimidone derivatives
EP2420493A4 (de) Haloalkylsulfonanilidderivat
IL216007A0 (en) Isoxazole-pyridine derivatives
EP2397480A4 (de) Diazepinedionederivate
EP2433940A4 (de) Spiroimidazolonderivat
ZA201106855B (en) Oxasiazole derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
ZA201104991B (en) Deoxyactagardine derivatives
HK1172894A1 (en) N1-acyl-5-fluoropyrimidinone derivatives n1--5-
HK1169623A1 (en) Pyrazinooxazepine derivatives
IL219603A0 (en) Imidazopyridine derivatives
HK1173134A1 (en) Substituted halophenoxybenzamide derivatives
GB0921967D0 (en) Novel Aryloxyanilide Derivatives
GB0918924D0 (en) Azaindole derivatives
ZA201104279B (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120904

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/12 20060101ALI20120829BHEP

Ipc: A01N 43/50 20060101AFI20120829BHEP

Ipc: C07D 405/14 20060101ALI20120829BHEP

Ipc: C07D 417/14 20060101ALI20120829BHEP

Ipc: C07D 403/14 20060101ALI20120829BHEP

Ipc: C07D 409/14 20060101ALI20120829BHEP

Ipc: C07D 413/14 20060101ALI20120829BHEP

Ipc: A61K 31/4184 20060101ALI20120829BHEP

Ipc: C07D 401/14 20060101ALI20120829BHEP

17Q First examination report despatched

Effective date: 20150324

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150804